Skip to main content
SpringerLink
Log in

OK-432 sclerotherapy of lymphatic malformation in the head and neck: factors related to outcome

  • Original Article
  • Published:
Pediatric Radiology Aims and scope Submit manuscript

Abstract

Background

No previous study to the best of our knowledge has examined the multiple factors related to the outcome of OK-432 sclerotherapy of lymphatic malformations.

Objective

This study aimed to assess factors related to the successful outcome of OK-432 sclerotherapy for lymphatic malformations in the head and neck region.

Materials and methods

During a 6-year period, OK-432 sclerotherapy was performed in 26 patients with lymphatic malformations. Several factors related to the efficacy of OK-432 sclerotherapy were evaluated, including the type (macrocystic or microcystic), the maximum lesion diameter, amount and hemorrhagic cytology of the aspirate, degree of aspiration, injected dose of OK-432 and post-therapy inflammation-related symptom. In all cases, ultrasound (US) follow-up was performed.

Results

Of the 26 cases, 13 (50%) showed successful elimination of the lymphatic malformations in the follow-up US after the initial session, and all successful cases were of the macrocystic type. The type of lymphatic malformation and the success of OK-432 sclerotherapy were significantly related (P = 0.0149). Of the 16 cases of complete aspiration, 11 (68.8%) showed a successful outcome. Further, of the 17 cases with inflammation-related symptom, 13 (76.5%) showed a successful outcome. While the degree of aspiration and presence of inflammation-related symptom showed a significant relationship with the success of OK-432 sclerotherapy (P < 0.05), no other factors showed a significant relationship.

Conclusion

The study results suggest that the macrocystic type and complete aspiration of cystic contents were important factors for the success of OK-432 sclerotherapy of lymphatic malformations, and that inflammation-related symptom was a predictor of a successful outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hamoir M, Plouin-Gaudon I, Rombaux P et al (2001) Lymphatic malformations of the head and neck: a retrospective review and a support for staging. Head Neck 4:326–337

    Google Scholar 

  2. Giguere CM, Bauman NM, Sato Y et al (2002) Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial. Arch Otolaryngol Head Neck Surg 10:1137–1144

    Article  Google Scholar 

  3. Banieghbal B, Davies MR (2003) Guidelines of the successful treatment of lymphangioma with OK-432. Eur J Pediatr Surg 2:103–107

    Google Scholar 

  4. Narkio-Makela M, Makel T, Saarinen P et al (2011) Treatment of lymphatic malformations of head and neck with OK-432 sclerotherapy induce systemic inflammatory response. Eur Ach Otorhinolaryngol 268:123–129

    Article  Google Scholar 

  5. Ogita S, Tsuto T, Tokiwa K et al (1987) Treatment of cystic hygroma in children with special reference to OK-432 therapy. Z kinderchir 5:279–281

    Google Scholar 

  6. Orvidas LJ, Kasperbauer JL (2000) Pediatric lymphangiomas of the head and neck. Ann Otol Rhinol Laryngol 4:411–421

    Google Scholar 

  7. Burrows PE, Mitri RK, Alomari A et al (2008) Percutaneous sclerotherapy of lymphatic malformations with doxycycline. Lymphat Res Biol 3:209–216

    Article  Google Scholar 

  8. Hall N, Ade-Ajayi N, Brewis C et al (2003) Is intralesional injection of OK-432 effective in the treatment of lymphangioma in children? Surgery 3:238–242

    Article  Google Scholar 

  9. Rautio R, Keski-Nisula L, Laranne J et al (2003) Treatment of lymphangiomas with OK-432 (Picibanil). Cardiovasc Intervent Radiol 1:31–36

    Google Scholar 

  10. Smith MC, Zimmerman MB, Burke DK et al (2009) OK-432 Collaborative Study Group. Efficacy and safety of OK-432 immunotherapy of lymphatic malformations. Laryngoscope 1:107–115

    Article  Google Scholar 

  11. Niramis R, Watanatittan S, Rattanasuwan T (2010) Treatment of cystic hygroma by intralesional bleomycin injection: experience in 70 patients. Eur J Pediatr Surg 20:178–182

    Article  CAS  PubMed  Google Scholar 

  12. Shiels WE 2nd, Kang DR, Murakami JW et al (2009) Percutaneous treatment of lymphatic malformations. Otolaryngol Head Neck Surg 141:219–224

    Article  PubMed  Google Scholar 

  13. Puig S, Aref H, Brunelle F (2003) Double-needle sclerotherapy of lymphangiomas and venous angiomas in children: a simple technique to prevent complications. AJR Am J Roentgenol 180:1399–1401

    Article  PubMed  Google Scholar 

  14. Schmidt B, Schimpl G, Hollwarth ME (1996) OK-432 therapy of lymphangiomas in children. Eur J Pediatr 155:649–652

    Article  CAS  PubMed  Google Scholar 

  15. Brewis C, Pracy JP, Albert DM (2000) Treatment of lymphangiomas of the head and neck in children by intralesional injection of OK-432 (Picibanil). Clin Otolaryngol Allied Sci 25:130–134

    Article  CAS  PubMed  Google Scholar 

  16. Luzzatto C, Midrio P, Tchaprassian Z et al (2000) Sclerosing treatment of lymphangiomas with OK-432. Arch Dis Child 82:316–318

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Sichel JY, Udassin R, Gozal D et al (2004) OK-432 therapy for cervical lymphangioma. Laryngoscope 114:1805–1809

    Article  CAS  PubMed  Google Scholar 

  18. Okazaki T, Iwatani S, Yanai T et al (2007) Treatment of lymphangioma in children: our experience of 128 cases. J Pediatr Surg 42:386–389

    Article  PubMed  Google Scholar 

  19. Yoo JC, Ahn Y, Lim YS et al (2009) OK-432 sclerotherapy in head and neck lymphangiomas: long-term follow-up result. Otolaryngol Head Neck Surg 140:120–123

    Article  PubMed  Google Scholar 

  20. Ogita S, Tsuto T, Nakamura K et al (1996) OK-432 therapy for lymphangioma in children: why and how does it work? J Pediatr Surg 31:477–480

    Article  CAS  PubMed  Google Scholar 

  21. Yang KD, Stone RM, Lee CS et al (1992) Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: implication of monocyte-derived neutrophil-activating factors. Cancer Immunol Immunother 35:277–282

    Article  CAS  PubMed  Google Scholar 

  22. Rho MH, Kim DW, Kwon JS et al (2006) OK-432 sclerotherapy of plunging ranula in 21 patients: it can be a substitute for surgery. AJNR Am J Neuroradiol 27:1090–1095

    CAS  PubMed  Google Scholar 

  23. Reismann M, Chaffarpour N, Luvall E et al (2013) Dynamic Toll-like receptor expression predicts outcome of sclerotherapy for lymphatic malformations with OK-432 in children. J Surg Res. doi:10.1016/j.jss.2013.09.037

    PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Radiology, Busan Paik Hospital, Inje University College of Medicine, 633-165, Gaegeum-dong, Busanjin-gu, Busan, Republic of Korea, 614-734

    Dong Wook Kim

Authors
  1. Dong Wook Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dong Wook Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, D.W. OK-432 sclerotherapy of lymphatic malformation in the head and neck: factors related to outcome. Pediatr Radiol 44, 857–862 (2014). https://doi.org/10.1007/s00247-014-2889-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00247-014-2889-0

Keywords

Search

Navigation